drugset / Trial / NCT00840411
Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study is to compare the relative bioequivalence of a test clarithromycin extended release formulation to an equivalent oral dose of the commercially available extended release clarithromycin in a test population of 66 adult subjects under fasting conditions.
Timeline
- Start
- 2002-09
- Primary completion
- 2002-10
- Completion
- 2002-10
Outcome
Met primary endpoint
registry Test/Ref Ratio of LS Means x 100 100.0 (90% CI 93.3 to 107.1) NCT00840411 ↗
registry Ratio of Least Squares Means 86.5 (90% CI 80.1 to 93.4) NCT00840411 ↗
registry Ratio of Least Squares Means 87.2 (90% CI 81.0 to 93.8) NCT00840411 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 500 mg | Oral |
Indications
No indication recorded.